NYU Langone Health
NYU Langone Health
Mineola, New York, United States6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube clear cell adenocarcinoma, fallopian tube disorder, fallopian tube endometrioid tumor, fallopian tube neoplasm, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian clear cell adenocarcinoma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, primary peritoneal serous adenocarcinoma | Recruiting | Phase 3 | 2026-09-14 | NCT04575935 | |
| A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older | Clostridoides Difficile Associated Disease | Recruiting | Phase 3 | 2026-09-09 | NCT07282665 | |
| A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | Biochemically Recurrent Prostate Cancer | Active, not recruiting | Phase 3 | 2026-07-07 | NCT05794906 | |
| Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors | Infections, Skin and Connective Tissue Diseases, nail disorder, paronychia, skin disorder, skin disorder caused by infection | Recruiting | Phase 2 | 2026-03-31 | NCT05639933 | |
| Ladarixin With Sotorasib in Advanced NSCLC | Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation | Recruiting | Phase 1 | 2025-12-30 | NCT05815173 | |
| CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Active, not recruiting | Phase 3 | 2025-12-01 | NCT05681351 |